Biological Agents: Weapons of Warfare and Bioterrorism, Molecular Diagnosis, vol.6, issue.4, pp.323-333, 2001. ,
DOI : 10.2165/00066982-200106040-00013
Botulinum toxin type B micromechanosensor, Proceedings of the National Academy of Sciences, vol.14, issue.2, pp.13621-13625, 2003. ,
DOI : 10.1016/0006-8993(85)90806-6
URL : http://www.pnas.org/content/100/23/13621.full.pdf
Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects, pp.473-476, 1993. ,
Production of Monovalent botulinus antitoxic serum types A and B, The Journal of Immunology, vol.8, pp.501-505, 1923. ,
Botulinum type A toxin neutralisation by specific IgG and its fragments: A comparison of mouse systemic toxicity and local flaccid paralysis assays, Toxicon, vol.48, issue.3, pp.246-254, 2006. ,
DOI : 10.1016/j.toxicon.2006.05.007
High-Affinity, Protective Antibodies to the Binding Domain of Botulinum Neurotoxin Type A, Infection and Immunity, vol.69, issue.1, pp.570-574, 2001. ,
DOI : 10.1128/IAI.69.1.570-574.2001
Characterization of Neutralizing Antibodies and Identification of Neutralizing Epitope Mimics on the Clostridium botulinum Neurotoxin Type A, Applied and Environmental Microbiology, vol.67, issue.7, pp.3201-3207, 2001. ,
DOI : 10.1128/AEM.67.7.3201-3207.2001
Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid, Vaccine, vol.20, issue.19-20, pp.2556-2561, 2002. ,
DOI : 10.1016/S0264-410X(02)00157-3
Hypersensitivity reactions associated with botulinal antitoxin, The American Journal of Medicine, vol.69, issue.4, pp.567-570, 1980. ,
DOI : 10.1016/0002-9343(80)90469-6
Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries, Infection and Immunity, vol.65, pp.3743-3752, 1997. ,
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody, Proceedings of the National Academy of Sciences, vol.287, issue.5458, pp.11346-11350, 2002. ,
DOI : 10.1126/science.287.5458.1664
URL : http://www.pnas.org/content/99/17/11346.full.pdf
Immunogenicity and Kinetics of Distribution and Elimination of Sheep Digoxin-Specific Igg and Fab Fragments in the Rabbit and Baboon, Clinical and Experimental Immunology, vol.36, pp.384-396, 1979. ,
, and Fab Botulinum Antitoxins in Mice, Immunopharmacology and Immunotoxicology, vol.150, issue.3, pp.397-408, 2003. ,
DOI : 10.1093/infdis/150.3.407
Modulating pharmacokinetics of an anti-interleukin-8 F(ab???)2 by amine-specific PEGylation with preserved bioactivity, International Journal of Pharmaceutics, vol.198, issue.1, pp.83-95, 2000. ,
DOI : 10.1016/S0378-5173(99)00458-5
ADAPTING PHARMACOKINETIC PROPERTIES OF A HUMANIZED ANTI-INTERLEUKIN-8 ANTIBODY FOR THERAPEUTIC APPLICATIONS USING SITE-SPECIFIC PEGYLATION, Cytokine, vol.16, issue.3, pp.106-119, 2001. ,
DOI : 10.1006/cyto.2001.0936
Therapeutic antibody fragments with prolonged in vivo half-lives, Nature Biotechnology, vol.217, issue.8, pp.780-783, 1999. ,
DOI : 10.1016/S0022-1759(98)00061-1
PEGylated antibodies and antibody fragments for improved therapy: a review, Advanced Drug Delivery Reviews, vol.54, issue.4, pp.531-545, 2002. ,
DOI : 10.1016/S0169-409X(02)00026-1
Growth of Clostridia and Preparation of Their Neurotoxins, pp.143-160, 1995. ,
DOI : 10.1007/978-3-642-85173-5_7
Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies, FEBS Letters, vol.23, issue.1-3, pp.299-306, 2004. ,
DOI : 10.1023/B:JOPC.0000016257.91979.06
A sensitive sandwich enzyme immunoassay for free or complexed Clostridium botulinum neurotoxin type A, Journal of Immunological Methods, vol.330, issue.1-2, pp.120-129, 2008. ,
DOI : 10.1016/j.jim.2007.11.006
Preparation of F(ab???)2 fragments from mouse IgG of various subclasses, Journal of Immunological Methods, vol.56, issue.2, pp.235-243, 1983. ,
DOI : 10.1016/0022-1759(83)90415-5
Immunogenicity of neurotoxins of Clostridium Botulinum in therapy with botulinum toxin, pp.93-107, 1994. ,
Genetic Diversity among Botulinum Neurotoxin-Producing Clostridial Strains, Journal of Bacteriology, vol.189, issue.3, pp.818-832, 2007. ,
DOI : 10.1128/JB.01180-06
URL : http://jb.asm.org/content/189/3/818.full.pdf
Independent evolution of neurotoxin and flagellar genetic loci in proteolytic Clostridium botulinum, BMC Genomics, vol.10, issue.1, 2009. ,
DOI : 10.1186/1471-2164-10-115
URL : https://bmcgenomics.biomedcentral.com/track/pdf/10.1186/1471-2164-10-115?site=bmcgenomics.biomedcentral.com
Novel Clostridium botulinum Toxin Gene Arrangement with Subtype A5 and Partial Subtype B3 Botulinum Neurotoxin Genes, Journal of Clinical Microbiology, vol.47, issue.7, pp.2349-2350, 2009. ,
DOI : 10.1128/JCM.00799-09
URL : http://jcm.asm.org/content/47/7/2349.full.pdf
Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization, Infection and Immunity, vol.73, issue.9, pp.5450-5457, 2005. ,
DOI : 10.1128/IAI.73.9.5450-5457.2005
URL : http://iai.asm.org/content/73/9/5450.full.pdf
Development of recombinant vaccines for botulinum neurotoxin, Toxicon, vol.36, issue.11, pp.1539-1548, 1998. ,
DOI : 10.1016/S0041-0101(98)00146-9
Protective Vaccination with A Recombinant Fragment of Clostridium-Botulinum Neurotoxin Serotype A Expressed from A Synthetic Gene in Escherichia-Coli, Infection and Immunity, vol.63, pp.2738-2742, 1995. ,
Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin, Toxicon, vol.39, issue.5, pp.651-657, 2001. ,
DOI : 10.1016/S0041-0101(00)00189-6
Clinical trial of human botulism immune globulin Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects, pp.477-482, 1993. ,
DOI : 10.1007/978-1-4757-9542-4_53
A Structural Perspective of the Sequence Variability Within Botulinum Neurotoxin Subtypes A1-A4, Journal of Molecular Biology, vol.362, issue.4, pp.733-742, 2006. ,
DOI : 10.1016/j.jmb.2006.07.040
Relationship of Effective Molecular-Size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-Soluble Polymers, Journal of Biological Chemistry, vol.263, pp.15064-15070, 1988. ,
Antibody Pharmacokinetics and Pharmacodynamics, Journal of Pharmaceutical Sciences, vol.93, issue.11, pp.2645-2668, 2004. ,
DOI : 10.1002/jps.20178
Pharmacokinetics and biodistribution of genetically engineered antibodies, Current Opinion in Biotechnology, vol.13, issue.6, pp.603-608, 2002. ,
DOI : 10.1016/S0958-1669(02)00352-X